95299-18-6Relevant articles and documents
NITROGENATED HETEROCYCLIC COMPOUND
-
Paragraph 1088, (2015/03/28)
The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.
PROCESS FOR PRODUCTION OF THIOPHENE COMPOUND AND INTERMEDIATE THEREOF
-
Page/Page column 10, (2010/11/17)
To provide a novel process for producing a 2-aryl-3-hydroxy-4-substituted carbonyl thiophene compound or an intermediate thereof useful as an intermediate for production of medicines and agricultural chemicals. A 2-aryl acetate compound represented by the formula (1): wherein R1 is an aryl group or the like, R4 is a C1-3 alkyl group or the like, and X is a leaving group, is reacted with a thioacetic acid compound to form a thioacetyl compound (3), the thioacetyl compound (3) is reacted with a vinyl ketone compound to form a γ-ketosulfide compound (5), which is cyclized under basic conditions to form a dihydrothiophene compound (6), and the dihydrothiophene compound (6) is oxidized by using an oxidizing agent to produce a 2-aryl-3-hydroxy-4-substituted carbonyl thiophene compound (7).
Novel benzimidazole derivatives as selective CB2 agonists
Pagé, Daniel,Balaux, Elise,Boisvert, Luc,Liu, Ziping,Milburn, Claire,Tremblay, Maxime,Wei, Zhongyong,Woo, Simon,Luo, Xuehong,Cheng, Yun-Xing,Yang, Hua,Srivastava, Sanjay,Zhou, Fei,Brown, William,Tomaszewski, Miroslaw,Walpole, Christopher,Hodzic, Leila,St-Onge, Stéphane,Godbout, Claude,Salois, Dominic,Payza, Keymal
scheme or table, p. 3695 - 3700 (2009/04/04)
The preparation and evaluation of a novel class of CB2 agonists based on a benzimidazole moiety are reported. They showed binding affinities up to 1 nM towards the CB2 receptor with partial to full agonist potencies. They also demonstrated good to excellent selectivity (>1000-fold) over the CB1 receptor.